Funding Arrangements (Details) - USD ($) $ in Millions |
1 Months Ended | |||||
|---|---|---|---|---|---|---|
Jul. 31, 2024 |
Jun. 30, 2023 |
Apr. 30, 2021 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Mar. 31, 2025 |
|
| CARB-X Agreement | ||||||
| Funding Arrangement [Line Items] | ||||||
| Grant receivable on unreimbursed, eligible costs incurred | $ 0.0 | $ 0.0 | ||||
| CARB-X Agreement | Minimum | ||||||
| Funding Arrangement [Line Items] | ||||||
| Potential funding committed by award | 11.7 | |||||
| National Institutes Of Health | ||||||
| Funding Arrangement [Line Items] | ||||||
| Potential funding amount of award to develop vaccine to prevent infections | $ 9.5 | $ 4.6 | $ 0.5 | |||
| National Institutes Of Health | Maximum | ||||||
| Funding Arrangement [Line Items] | ||||||
| Potential funding period of award to develop vaccine to prevent infections (in years) | 5 years | 5 years | 5 years | |||
| Cost Reimbursement Sub-Award Agreement | ||||||
| Funding Arrangement [Line Items] | ||||||
| Grant receivable on unreimbursed, eligible costs incurred | $ 0.0 | $ 0.0 | ||||